Interventional Oncology at J&J

Intratumoral treatments

What is Interventional Oncology (INTO) at J&J?

INTO at J&J is a Research & Development enterprise group working to develop intratumoral treatments, a promising growth area within interventional oncology, by integrating the expertise of Johnson & Johnson. We use a multidisciplinary approach to help accelerate the company's bold vision to eliminate cancer by developing the portfolio and procedures to deliver drugs directly into tumors.



Johnson & Johnson is highly differentiated by its two sectors: Innovative Medicine and MedTech. By integrating the expertise of both sectors, we believe we are uniquely positioned to develop intratumoral therapies, technology, and procedures for solid tumors.

Why intratumoral treatments?

Intratumoral treatments are anticipated to have several potential benefits that can help address clinical unmet needs along the patient journey.

These approaches are designed to:[1]

Enable higher drug concentrations within tumors

Provide higher concentrations of local therapy to kill the tumor and activate anti-tumor immunity

Minimize exposure to healthy tissues

Make possible a better risk-benefit proposition especially for treatment of early cancer

Unlock new therapies

Enable the use of immunotherapies, which cannot be delivered systemically

Clinical trials

INTO is conducting multiple clinical trials focusing on innovative therapies aimed at improving patient outcomes. These trials include targeted therapies as well as combination approaches.

Recruitment of sites and patients in these trials is ongoing, and we encourage healthcare professionals interested in participating or referring eligible patients to connect with us for further details.

Johnson&Johnson

Data rates may apply

By joining this collaborative effort, you can contribute to pivotal research that could shape future cancer care.
For more information, please contact us at:
into_scientificaffairs@its.jnj.com

Our approach to partnering

External Innovation is at the core of INTO's mission to develop transformative intratumoral and locally delivered therapies by harnessing the extensive expertise and global reach of Johnson & Johnson's Innovative Medicine and MedTech sectors. We are actively recruiting external collaborations to deliver drugs directly into visceral tumors with the highest unmet needs, ultimately working to maximize therapeutic benefit while minimizing toxicity and side effects.

We are actively seeking partnerships with biopharma, academic, and clinical institutions to find novel intratumoral therapies, accelerate asset development, and shape future research through collaboration and investment.

Clinical expertise

Medical Oncology, Radiation Oncology, Interventional Pulmonology, Interventional Radiology, and Thoracic Surgery

Scientific expertise

From Discovery to Late-Stage Clinical Development such as Pharmaceutical and Engineering Sciences, Biomarker Research, and AI/Data Sciences

Engineering expertise

To maximize efficacy, minimize user variability, and enable scale

Partner with us

The INTO External Innovation team is seeking external innovations to further our intratumoral portfolio in the following areas:

Innovative intratumoral therapies

New approaches may incorporate cytotoxic agents (ideally immunogenic cell death inducers), immunostimulatory energy or agents, radio-enhancers/sensitizers, and cell therapies. We seek to expand the use of controlled release and localized depot drug delivery technologies, including small molecule, protein, and RNA delivery approaches

Integrated delivery procedure solutions

Developing, expanding, and fine-tuning new technologies will empower our INTO team and its partners to plan, deliver, monitor, and confirm success of intratumoral therapy delivery

Johnson&Johnson

Contact us

We are seeking external innovations to further our intratumoral portfolio. Contact us for partnership opportunities.
ra-intoie@its.jnj.com

Data rates may apply

1. Brito-Orama S, Sheth RA. *J Immunother Precis Oncol.* 2023;6:84–90.
© Johnson & Johnson and its affiliates 2025 10/25 cp-520752v2